Investment
Features
FeesSafety
Academy
More
Pluang+

Vail Resorts reports lower 2026 earnings due to poor weather, expects recovery in 2027 with new investments and efficiency plans.

Company Fundamentals
28 Sep 2026
PRNewsWire
View Source
Bearish
Vail Resorts reports lower 2026 earnings due to poor weather, expects recovery in 2027 with new investments and efficiency plans.

Vail Resorts reported a net income of $147.5 million for fiscal 2026, down from $280 million the previous year, mainly due to historically low snowfall impacting ski season revenue. Resort EBITDA also declined to $745.7 million, affected by weather and one-time costs. Despite a 12% drop in season pass sales for 2026/2027, the company expects a rebound in fiscal 2027 with projected net income between $158 million and $233 million, driven by improved weather, pricing strategies, and $25 million in cost savings from its resource efficiency plan. Vail Resorts is investing in lift upgrades and technology to enhance guest experience and operational efficiency.

Vail Resorts fiscal 2026 results and fiscal 2027 outlook provide context for consumer cyclical sector activity. For readers following this sector, here is Pluang's market snapshot as of Sep 29, 2026 02:21 WIB: Among 112 US consumer cyclical stocks, 46 rose and 66 fell. Notable movers include RIVN at USD 14.84 with a 4.10% drop and 100% buy order activity, LCID at USD 3.90 down 4.05% with 86% buy orders, and AAP at USD 40.10 down 3.91% with full buy interest. Typical hold times range from 44 to 61 days on Pluang.

More News

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...

Market News
Bearish
1 hour ago
Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...

Market News
Bullish
1 hour ago
Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...

Market News
Bullish
2 hours ago
Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...

Market News
Neutral
2 hours ago
Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App